ArticleTherapeutic advances in gastroenterology2025
Defining partial response in inflammatory bowel disease: a Delphi consensus and economic evaluation.
Article in Therapeutic advances in gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Therapeutic goals in inflammatory bowel disease (IBD) are constantly evolving due to novel medical options and diagnostic tools, yet unmet clinical needs persist. Objectives: We aimed to establish a consensus definition for partial responders in clinical practice, considered as patients failing to meet defined objectives within the desired time frame. Design: A two-round Delphi consultation was held with IBD-specialized gastroenterologists. Methods: The 22-item questionnaire covered four clinical scenarios: (1) moderate ulcerative colitis (UC); (2) acute severe UC; (3) luminal Crohn's disease (CD); and (4) perianal CD. Consensus was defined when ⩾70% of panellists agreed with a statement, rated using a 7-point Likert scale. We also analysed the associated annual costs for partial responders and patients in remission according to the agreed long-term definitions, based on a literature review and the experience of the scientific committee. Medication costs were excluded from the analysis. Results: Sixty Spanish gastroenterologists with extensive experience in IBD management participated in the consultation. Consensus was achieved on partial response definitions with different criteria over time, including clinical scores, biomarkers and imaging or endoscopic examinations. The annual cost for partial responders and patients in remission was estimated at €2570.40 and €820.20 for UC, €1607.30 and €718.0 for luminal CD and €2886.70 and €888.80 for perianal CD, respectively. Conclusion: The concept of partial responders has been defined in four clinical scenarios. Patients achieving prolonged remission could provide 55%-70% savings in non-pharmacological resource use and associated costs. Our study could help healthcare professionals in decision-making, ultimately improving patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.